Potential Side Effects and Digestive Changes The most common adverse effects of Wegovy involve the gastrointestinal system, with nausea, diarrhoea, vomiting, constipation, and abdominal pain reported in clinical trials, as detailed in the MHRA-approved SmPC
Focus on protein, exercise, sleep, and meal structure
However, the role of mitophagy regulators such as PINK1/PRKN, BNIP3, and NIX in pancreatic tumorigenesis and progression is dynamic and intricate, as demonstrated in transgenic PDAC mouse models [53, 58]
Therefore, they are nowadays recommended as first line therapy in patients with T2DM and atherosclerotic cardiovascular disease to reduce events, regardless of baseline or target HbA1c and concomitant glucose-lowering medication according to the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes [31]